$LIVN

Tezel Ahmet sold (to issuer) $669K of LIVN

Tezel Ahmet (Chief Innovation Officer) sold (to issuer) 8,589 shares of LivaNova PLC (LIVN) at $77.86 ($0.67M total) on 2026-08-11.

Original reporting
SEC EDGAR · Tezel Ahmet
Published Aug 13, 2026, 8:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LIVN
Neutral
high confidence
Mentioned
$LIVN
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LIVNNeutralLow
01

Why it matters

The newest disclosed fact is the specific insider sale size, price, and post-transaction holdings; it does not include any new company performance, guidance, or corporate event.

02

Market read

Traders may note insider selling, but the filing lacks any fundamental catalyst and is unlikely to drive repricing by itself.

03

What to watch

No context is given on whether the insider had prior grants, tax obligations, or whether the sale is part of a broader compensation program.

Relevance 5/10Novelty 3/10Timing: Filed 2026-08-13 after-hours; reflects 2026-08-11 transaction.

Background

The article is an SEC Form 4 insider transaction disclosure for LivaNova PLC.

Company-level read

Ticker impact

$LIVNNeutralHigh confidence
Context

LivaNova Form 4 shows Chief Innovation Officer Tezel Ahmet sold 8,589 shares to the issuer at $77.86 on 2026-08-11.

Expected impact

Likely minimal near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and no accompanying company guidance, deal, or regulatory action in the text.

Market effects

No sector read-through is provided beyond a single insider sale.

None indicated.

None indicated.

Counterpoint

The sale to the issuer could be administrative (for example, buyback participation or plan mechanics) rather than a bearish view.

Key entities

  • LivaNova PLC

    Subject of the Form 4 insider transaction disclosure.

  • Tezel Ahmet

    Chief Innovation Officer who sold shares to the issuer.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LIVNMedAI 8/10

LivaNova (LIVN) Q2 2026 Earnings Call Transcript

LivaNova (LIVN) reported Q2 2026 revenue of $390.6 million, up 10.8% reported and 9.8% constant currency, and adjusted diluted EPS of $1.26. Adjusted gross margin rose to 71.0%. Full-year 2026 revenue guidance was raised to 8% to 9% constant-currency growth, and adjusted EPS to $4.30 to $4.40, while free cash flow guidance was lowered to $140 million to $160 million.

$LIVNMedAI 8/10

LivaNova PLC Q2 2026 Earnings Call Summary

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.

$LIVNHighAI 9/10

LivaNova Q2 Earnings Call Highlights

LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.

$LIVNHighAI 9/10

LivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LivaNova PLC (Nasdaq: LIVN) reported Q2 2026 revenue of $390.6M, up 10.8% reported and 9.8% constant currency. Adjusted diluted EPS was $1.26. It raised full-year 2026 revenue guidance to 8% to 9% constant currency and adjusted diluted EPS to $4.30 to $4.40. It also signed a long-term supply agreement with Thermo Fisher for oxygenator components.

$LIVNHighAI 9/10

Why is LivaNova stock climbing today?

LivaNova shares rose 1.3% in after-hours to $86.42 after the company reported Q2 2026 results. Adjusted EPS was $1.26 vs $1.09 expected, and revenue was $390.6M vs $380.57M. LivaNova raised full-year 2026 adjusted diluted EPS guidance to $4.30-$4.40 (midpoint $4.35). KeyBanc lifted its price target to $92 from $83.

$LIVNHigh

LivaNova PLC (LIVN): Results of Operations and Financial Condition

LivaNova PLC (LIVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q2026earningspressrelease.htm EX-99.1 Document EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance – Delivered double-digit reported revenue growth of 10.8%, with constant-currency rev